Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

533 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lack of O-GlcNAcylation enhances exercise-dependent glucose utilization potentially through AMP-activated protein kinase activation in skeletal muscle.
Murata K, Morino K, Ida S, Ohashi N, Lemecha M, Park SY, Ishikado A, Kume S, Choi CS, Sekine O, Ugi S, Maegawa H. Murata K, et al. Among authors: ida s. Biochem Biophys Res Commun. 2018 Jan 8;495(2):2098-2104. doi: 10.1016/j.bbrc.2017.12.081. Epub 2017 Dec 15. Biochem Biophys Res Commun. 2018. PMID: 29253568
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Inoue H, Morino K, Ugi S, Tanaka-Mizuno S, Fuse K, Miyazawa I, Kondo K, Sato D, Ohashi N, Ida S, Sekine O, Yoshimura M, Murata K, Miura K, Arima H, Maegawa H; SUMS-ADDIT-1 Research group. Inoue H, et al. Among authors: ida s. J Diabetes Investig. 2019 Jul;10(4):1012-1021. doi: 10.1111/jdi.12985. Epub 2019 Jan 21. J Diabetes Investig. 2019. PMID: 30536746 Free PMC article. Clinical Trial.
Microbiome potentiates endurance exercise through intestinal acetate production.
Okamoto T, Morino K, Ugi S, Nakagawa F, Lemecha M, Ida S, Ohashi N, Sato D, Fujita Y, Maegawa H. Okamoto T, et al. Among authors: ida s. Am J Physiol Endocrinol Metab. 2019 May 1;316(5):E956-E966. doi: 10.1152/ajpendo.00510.2018. Epub 2019 Mar 12. Am J Physiol Endocrinol Metab. 2019. PMID: 30860879 Free article.
Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial.
Horibe K, Morino K, Miyazawa I, Tanaka-Mizuno S, Kondo K, Sato D, Ohashi N, Ida S, Yanagimachi T, Yoshimura M, Itoh R, Murata K, Miura K, Arima H, Fujita Y, Ugi S, Maegawa H; SUMS-ADDIT-2 Research group. Horibe K, et al. Among authors: ida s. Diabetes Res Clin Pract. 2022 Apr;186:109781. doi: 10.1016/j.diabres.2022.109781. Epub 2022 Feb 15. Diabetes Res Clin Pract. 2022. PMID: 35181350 Clinical Trial.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
533 results